Ozempic vs Wegovy: Same Ingredient, Different Medical Context

Ozempic and Wegovy contain the same drug, semaglutide, made by the same company. The differences are what each is approved for, how high the dose goes, and how insurance treats them. Ozempic is approved for type 2 diabetes and tops out at 2 mg a week. Wegovy is approved for chronic weight management and goes up to 2.4 mg a week, and since 2026 there's a 7.2 mg Wegovy HD dose and a daily Wegovy pill too.

In practice, the right choice usually comes down to one question: do you have type 2 diabetes? Here's how the two compare on dose, results, cost and coverage as of October 2026.

Semaglutide copies a gut hormone called GLP-1, which lowers blood sugar and reduces appetite. Novo Nordisk developed it first for diabetes and sold it as Ozempic in 2017. When trials showed how much weight people lost at higher doses, the company ran a separate set of obesity trials and got the higher-dose version approved in 2021 under a different name, Wegovy.

Two brands for one molecule isn't unusual, but it causes real confusion. The pens look different, the doses don't match, and insurers treat them as completely separate products. If you've wondered why your friend gets "Ozempic" covered for $25 while you're denied Wegovy, the label is the reason. Our explainer on how Ozempic causes weight loss covers the biology.

At the doses each is designed for, Wegovy produces more weight loss, simply because it goes higher. In the STEP 1 trial, adults with obesity and without diabetes lost about 15% of their body weight on Wegovy 2.4 mg over 68 weeks. In people with type 2 diabetes, Ozempic at 1 to 2 mg led to an average loss of about 6 to 7 kg (13 to 15 lb) over 40 weeks.

That comparison isn't perfectly fair, because people with diabetes tend to lose less weight on GLP-1 drugs in general. But the direction is clear: if weight loss is the main goal, Wegovy's dose range was built for it. And for people who need more, Wegovy HD (7.2 mg), approved in March 2026, produced about 21% average weight loss in its main trial. It's approved for adults who have already been on 2.4 mg.

For type 2 diabetes, Ozempic is the product built for the job. It's approved to lower A1C and to reduce heart and kidney risk in people with diabetes, and it's far more likely to be covered by insurance for that use. Wegovy also lowers blood sugar, and people with diabetes can be prescribed it for weight management, but its label isn't centered on glucose control. For the full diabetes picture, see Ozempic for diabetes.

Cash prices are now close. Novo Nordisk sells both through NovoCare at $349 a month for most injection doses, with Ozempic 2 mg at $499 and Wegovy HD around $399. The Wegovy pill starts at $149 a month for the lowest dose.

Insurance is where they split. Plans almost always cover Ozempic for type 2 diabetes, often after prior authorization. Many employer plans exclude weight-loss drugs entirely, so Wegovy may not be covered at all. On Medicare, Ozempic is covered for diabetes, while Wegovy is covered when prescribed to lower cardiovascular risk and, since July 2026, for eligible members through the GLP-1 Bridge at a $50 copay. Our insurance guide explains how to check your plan.

Yes, with your prescriber's help, and it's common when someone without diabetes started on Ozempic and now has Wegovy coverage, or wants a higher dose. Because it's the same drug, people usually don't have to start over at 0.25 mg; prescribers typically move to a Wegovy dose close to the current Ozempic dose and continue stepping up. Switching from Wegovy to Ozempic works the same way in reverse.

Don't take both at once, and don't convert doses yourself. If you're also weighing tirzepatide or the new pills, our Ozempic alternatives guide compares all the options.

Because they're the same molecule, Ozempic and Wegovy share the same side effects and warnings: nausea, diarrhea, vomiting and constipation are common early on, and rarer risks include pancreatitis, gallbladder problems and kidney injury from dehydration. Neither should be used by people with a personal or family history of medullary thyroid cancer or MEN 2. Higher doses tend to bring more stomach side effects, which is why Wegovy's dose climbs slowly. See Is Ozempic Safe? for the details.

Still wondering whether Ozempic itself can be prescribed for weight loss? See is Ozempic approved for weight loss for the short answer and what off-label use means for coverage.

If your comparison is with Lilly's drug rather than with Novo's own weight-loss brand, Ozempic vs Mounjaro covers the trial numbers, the 2026 costs and how a switch between the two is done.

Ozempic and Wegovy are the same medicine packaged for different patients. If you have type 2 diabetes, Ozempic is usually the right and best-covered choice. If your goal is weight loss without diabetes, Wegovy is the version approved for it, reaches higher doses, and is the one Medicare's weight-loss program covers. Cash prices are now similar, so for most people the decision comes down to diagnosis and insurance, not the drug.